In vivo spectrofluorometric analysis during photodynamic therapy (PDT) is a fundamental tool to obtain information about drug bleaching kinetics. Using a portable spectrofluorometer with an excitation source emitting at 400nm wavelength and a spectral analyzer ranging from 500nm to 800nm, the evolution of the meta-tetra(hydroxyphenyl) chlorin (m-THPC) photosensitizer fluorescence spectrum at the tumoral tissue of BALB/c murines with fibrosarcoma located at their flank was followed up. Ex vivo fluorescence measurements of the tumor and skin were also performed with the aim of better characterizing the in vivo signal at different parts of the tumor. PDT was performed employing a LED 637nm light source. Fluorescence at different parts of the tumor and at the tail and armpit of mice was measured immediately after injection and followed daily. The average fluorescence intensity in the tumor reached a maximum after 24-72h. Subsequently, illuminations 24, 48, 72 and 96h post-injection were performed, and the fluorescence was measured immediately before and after each illumination. Eventually, 24h post-illumination, the fluorescence at certain parts of the tumor increased in comparison with that measured immediately after illumination. This effect, named "rebound effect", was due to the new local accumulation of the drug, and was used to perform a second illumination on some mice to increase the amount of photodynamic reaction and significantly improve the PDT outcome. These results are encouraging to optimize PDT in the proposed animal model, thinking about the possible translation to humans.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pdpdt.2017.11.006 | DOI Listing |
Tzu Chi Med J
September 2024
School of Medicine, Tzu Chi University, Hualien, Taiwan.
Objectives: Gastric cancer (GC) is one of the most malignant tumors. Mounting studies highlighted gastric cancer stem cells (GCSCs) were responsible for the failure of treatment due to recurrence and drug resistance of advanced GC. However, targeted therapy against GCSC for improving GC prognosis suffered from lack of suitable models and molecular targets in terms of personalized medicine.
View Article and Find Full Text PDFRev Med Suisse
January 2025
Service d'oncologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
New therapeutic agents in oncology are emerging rapidly, both in terms of the number of approved drugs and the technological and biological innovation of new treatments. Antibody-drug conjugates (ADC) offer a promising cancer therapy by specifically targeting tumor cells. ADC are composed of a monoclonal antibody recognizing the tumor cell via specific antigens, coupled with a potent cytotoxic agent that resembles classical chemotherapy.
View Article and Find Full Text PDFSci Data
January 2025
Department of Biostatistics, School of Public Health, Harbin Medical University, Harbin, 150081, China.
Gastric cancer (GC) is the third leading cause of cancer death worldwide. Its clinical course varies considerably due to the highly heterogeneous tumour microenvironment (TME). Decomposing the complex TME from histological images into its constituent parts is crucial for evaluating its patterns and enhancing GC therapies.
View Article and Find Full Text PDFJ Cardiol Cases
January 2025
Department of Cardiology, Hokko Memorial Hospital, Sapporo, Japan.
Unlabelled: Outpouching of the heart ventricles, especially of the right ventricle, is rare. Here, we report the case of a 60-year-old male, referred to our institution with an outpouched structure at the right ventricular apex. The patient had no cardiac events.
View Article and Find Full Text PDFCurr Pharm Biotechnol
January 2025
Department of Pharmacology, College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China.
Breast cancer (BC) is a common malignant tumor. BC is serious and has a high mortality rate. The incidence of BC has increased in recent years.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!